Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, Yesterday
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.

Infections predict death in diffuse large B cell lymphoma

16 Jul 2017
GIS, CSI make first collaborative discovery on cancer progression

Diffuse large B cell lymphoma (DLBCL) patients with neutropenia and multiple comorbidities have a high risk of death and infection, a new study reports. Moreover, infection is an independent predictor of survival.

In a cohort of 325 DLBCL patients, Charlson Comorbidity Index (CCI) scores of 3 to 5 (hazard ratio [HR], 2.16; 95 percent CI, 1.71 to 2.74; p<0.001) and ≥6 (HR, 3.91; 2.34 to 6.28; p<0.001) were significantly correlated with infections.

Having Eastern Cooperative Oncology Group (ECOG) scores of 1 (HR, 2.09; 1.46 to 3.01; p<0.001), 2 (HR, 3.33; 2.22 to 5.04; p<0.001) and 3 (HR, 3.36; 1.99 to 5.66; p<0.001), and neutropenia within 48 hours (HR, 2.46; 1.91 to 3.17; p<0.001) were also associated with increased risks of infection.

Over the study duration of 10 years, 99 deaths (30.5 percent) were reported. The median time from diagnosis to death was 273 (129 to 636) days. The most common cause of death was progressive lymphoma (58.6 percent), followed by infection (12.1 percent) and other cancers (5.5 percent).

CCI scores of 3 to 5 (HR, 4.34; 2.00 to 6.33; p<0.001) and ≥6 (HR, 7.36; 3.38 to 16.00; p<0.001), an ECOG status of 1 (HR, 2.61; 1.02 to 6.66; p=0.045) and 3 or 4 (HR, 7.16; 2.04to 25.06; p=0.002), and infection upon admission (HR, 3.27; 2.03 to 5.27; p<0.001) were all independent and significant predictors of survival.

Participants were recruited from Monash Health I Melbourne, Australia, and were receiving rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) or similar chemotherapies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, Yesterday
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.